Citations to this article

Federica Di Nicolantonio, Sabrina Arena, Josep Tabernero, Stefano Grosso, Francesca Molinari, Teresa Macarulla, Mariangela Russo, Carlotta Cancelliere, Davide Zecchin, Luca Mazzucchelli, Takehiko Sasazuki, Senji Shirasawa, Massimo Geuna, Milo Frattini, José Baselga, Margherita Gallicchio, Stefano Biffo, Alberto Bardelli
Published in Volume 120, Issue 8
J Clin Invest. 2010; 120(8):2858–2866 doi:10.1172/JCI37539

Total citations by year

Year: 2013 2012 2011 2010 Total
Citations: 1 11 25 2 39
Citation information

Citations to this article (39)

Title and authors Publication Year
Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients
B Karakas, D Colak, N Kaya, H Ghebeh, A Al-Qasem, F Hendrayani, M Toulimat, T Al-Tweigeri, BH Park, A Aboussekhra
Cancer biology & therapy 2013
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
AM Gonzalez-Angulo, GR Blumenschein
Cancer Treatment Reviews 2012
Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer
S Keck, AC Glencer, HS Rugo
Future Oncology 2012
Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma
C Rodríguez-Antona, J García-Donas
Pharmacogenomics 2012
Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer
B Weigelt, J Downward
Frontiers in Oncology 2012
Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer
M Yu, WM Grady
Therapeutic advances in gastroenterology 2012
Role of Phosphatidylinositol-3-Kinase Pathway in Head and Neck Squamous Cell Carcinoma
L Du, J Shen, A Weems, SL Lu
Journal of Oncology 2012
A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors
DL Reidy-Lagunes, E Vakiani, MF Segal, EM Hollywood, LH Tang, DB Solit, MC Pietanza, M Capanu, LB Saltz
Cancer 2012
K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas
F Wei, Y Liu, AC Bellail, JJ Olson, SY Sun, G Lu, L Ding, C Yuan, G Wang, C Hao
Cancer Letters 2012
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
D Lipson, M Capelletti, R Yelensky, G Otto, A Parker, M Jarosz, JA Curran, S Balasubramanian, T Bloom, KW Brennan, A Donahue, SR Downing, GM Frampton, L Garcia, F Juhn, KC Mitchell, E White, J White, Z Zwirko, T Peretz, H Nechushtan, L Soussan-Gutman, J Kim, H Sasaki, HR Kim, S Park, D Ercan, CE Sheehan, JS Ross, MT Cronin, PA Jänne, PJ Stephens
Nature Medicine 2012
Phase II trial of temsirolimus in patients with metastatic breast cancer
GF Fleming, CX Ma, D Huo, H Sattar, M Tretiakova, L Lin, OM Hahn, FO Olopade, R Nanda, PC Hoffman, MJ Naughton, T Pluard, SD Conzen, MJ Ellis
Breast Cancer Research and Treatment 2012
PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies
L Willems, J Tamburini, N Chapuis, C Lacombe, P Mayeux, D Bouscary
Current Oncology Reports 2012
Somatic Mutations in PIK3CA and Activation of AKT in Intraductal Tubulopapillary Neoplasms of the Pancreas :
H Yamaguchi, Y Kuboki, T Hatori, M Yamamoto, K Shiratori, S Kawamura, M Kobayashi, M Shimizu, S Ban, I Koyama, M Higashi, N Shin, K Ishida, T Morikawa, F Motoi, M Unno, A Kanno, K Satoh, T Shimosegawa, H Orikasa, T Watanabe, K Nishimura, Y Harada, T Furukawa
American Journal of Surgical Pathology 2011
PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
F Janku, JJ Lee, AM Tsimberidou, DS Hong, A Naing, GS Falchook, S Fu, R Luthra, I Garrido-Laguna, R Kurzrock
PloS one 2011
Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine
JD Holbrook, JS Parker, KT Gallagher, WS Halsey, AM Hughes, VJ Weigman, PF Lebowitz, R Kumar
Journal of Translational Medicine 2011
Liposarcoma: Molecular Genetics and Therapeutics
R Conyers, S Young, DM Thomas
Sarcoma 2011
Rapamycin and mTORC1 Inhibition in the Mouse: Skin Cancer Prevention
M Athar, L Kopelovich
Cancer prevention research (Philadelphia, Pa.) 2011
The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer
J Roper, MP Richardson, WV Wang, LG Richard, W Chen, EM Coffee, MJ Sinnamon, L Lee, PC Chen, RT Bronson, ES Martin, KE Hung
PloS one 2011
Molecular Tumor Profiling for Prediction of Response to Anticancer Therapies
Z Walther, J Sklar
The Cancer Journal 2011
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
TW Miller, BN Rexer, JT Garrett, CL Arteaga
Breast cancer research : BCR 2011
Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors
C Delbaldo, S Albert, C Dreyer, MP Sablin, M Serova, E Raymond, S Faivre
Targeted Oncology 2011
Impairment of Cytoplasmic eIF6 Activity Restricts Lymphomagenesis and Tumor Progression without Affecting Normal Growth
A Miluzio, A Beugnet, S Grosso, D Brina, M Mancino, S Campaner, B Amati, A de Marco, S Biffo
Cancer Cell 2011
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
LS Steelman, RA Franklin, SL Abrams, W Chappell, CR Kempf, J Bäsecke, F Stivala, M Donia, P Fagone, F Nicoletti, M Libra, P Ruvolo, V Ruvolo, C Evangelisti, AM Martelli, JA McCubrey
Leukemia 2011
Current and future directions in mammalian target of rapamycin inhibitors development
A Fasolo, C Sessa
Expert Opinion on Investigational Drugs 2011
Mechanisms of mTOR inhibitor resistance in cancer therapy
JS Carew, KR Kelly, ST Nawrocki
Targeted Oncology 2011

Advertisement